FREQUENTLY ASKED QUESTIONS
Feromics’ Intelligent Design (ID) Platform is a proprietary, function-first single-cell system that integrates advanced immunology with AI-driven bioinformatics. It enables the rapid discovery of novel immune targets by assessing cellular function at high resolution, delivering deeper insights than traditional surface marker or gene expression approaches.
We collaborate with pharmaceutical and biotech companies through co-development partnerships, joint research programs, and technology licensing. Feromics offers access to its ID Platform, scientific expertise, and validated functional datasets to accelerate immunotherapy development from discovery to clinical translation.
Feromics develops a portfolio of preclinical-stage assets, including novel drug targets, therapeutic candidates, diagnostic signatures, and proprietary datasets. These assets are derived through our functional immunomics approach, which reveals actionable insights into immune behavior at the single-cell level.
Feromics generates high-dimensional functional immune data using proprietary single-cell assays. Our integrated bioinformatics pipeline analyzes cellular behavior, signaling, and phenotypes in context—prioritizing real functional outcomes over static gene or protein profiles.
Bioinformatics is essential to Feromics’ platform, enabling us to decode vast immune datasets with precision. Our algorithms connect cellular function with clinical relevance, uncovering hidden immune dynamics that guide therapeutic discovery and patient stratification.